Synergistic effect of targeted inhibition of MEK/ERK and PI3K/AKT survival signaling pathways on induction of apoptosis in melanoma

Journal of Sichuan University (Medical Science)

Volumn 45, Issue 3, 2014, Pages 355-361

  Wang, Xin Yuan ^a   Cheng, Yao ^a   Du, Ji Pei ^a   Chen, De Gao ^a   Yang, Xue Shan ^a   Yang, Zhi Mei ^a   Huang, Ning ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Effect MEK ERK; Melanoma; PI3K AKT; Synergistic

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; NITRILE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; DRUG EFFECTS; HUMAN; MELANOMA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTADIENES; CELL LINE, TUMOR; CHROMONES; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MORPHOLINES; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84903135289     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist, 2011;16(1):5-24.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer. J Clin, 2010;60(5):277-300.
3. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a Phase M, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol, 2009;27(17):2823- 2830.
4. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010;467(7315):596-599.
5. Nazarian R, Shi HB, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010;468(7326):973-977.
6. Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J, 2012;18(2):142-147.
7. Yajima I, Kumasaka MY, Thang ND, et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract, 2012;2012:354191. doi:10. 1155/2012/354191.
8. Yang H, Higgins B, Kolinsky K, et al. RG7204(PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res, 2010;70(13):5518-5527.
9. Nguyen D, Zhang X, Hersey P. Regulation of TRAIL induced apoptosis of fresh melanoma isolates. Clin Cancer Res, 2001;7(3):966s-973s.
10. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell, 2012;150(2):251-263.
11. Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res, 2011;71(7):2750-2760.
12. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol, 2012;30(20), 2522-2529.
13. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med, 2012;367(18):1694-1703.
14. Ott PA, Hamilton A, Min C, et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One, 2010;5(12):e15588.
15. Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res, 2006;16(4):267-273.
16. Abdala-Valencia H, Berdnikovs S, Cook-Mills JM. Mechanisms for vascular cell adhesion molecule-1 activation of ERK1/2 during leukocyte transendothelial migration. PLoS One, 2011;6(10):e26706.
17. Pratsinis H, Constantinou V, Pavlakis K, et al. Exogenous and autocrine growth factors stimulate human intervertebral disc cell proliferation via the ERK and Akt pathways. J Orthop Res, 2012;30(6):958-964.
18. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF - targeted melanoma cells. Cancer Res, 2010;70(16):6670-6681.
19. Aguissa-Toure A-H, Li G. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci, 2012;69(9):1475-1491.
20. Mitsiades N, Chew SA, He B, et al. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci, 2011;52(10):7248-7255.
21. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov, 2014;4(1):94-109.
22. Davies MA, Stemke-Hale K, Lin E, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res, 2009;15(24):7538-7546.
23. Li Y, Takahashi M, Stork PJ. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signalregulated kinase and is inhibited by protein kinase a phosphorylation. J Biol Chem, 2013;288(38):27646- 27657.